Worldwide, give the high incidence of ovarian cancer, the opportunity to identify BRCA1/2 carriers at the time of their cancer diagnosis – and those at risk for developing disease – can impact therapeutic interventions. This evidence concerns the gene BRCA1 and ovarian carcinoma.